Information Provided By:
Fly News Breaks for August 19, 2019
Aug 19, 2019 | 07:22 EDT
H.C. Wainwright analyst Swayampakula Ramakanth downgraded Trillium Therapeutics to Neutral from Buy, stating that the stock's 80% drop in price to 26c per share from $1.32 in the last six months could "lead to a cash crunch," leaving significant risk for its ability to raise sufficient capital to fund ongoing clinical studies. Additionally, the company has been unable to secure a replacement and remains without a CEO since Niclas Stiernholm resigned on April 30, noted Ramakanth.
News For TRIL From the Last 2 Days
There are no results for your query TRIL